Kura Oncology to Participate in Three Upcoming Investor Conferences
October 30, 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix, GlycoMimetics, Arog, Delta-Fly, Jasper, Jazz, Daiichi Sankyo, Amgen, AbbVie, Merck, Eli Lilly
August 07, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix, GlycoMimetics, Arog, Delta-Fly,...
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
August 07, 2023 07:00 ET
|
Marker Therapeutics
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
June 14, 2023 07:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2023 16:01 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress
June 11, 2023 03:45 ET
|
Kura Oncology, Inc.
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH...
Kura Oncology to Participate in Stifel Targeted Oncology Days
April 18, 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
AB Science tiendra une conférence virtuelle sur sa plateforme de déstabilisateurs de microtubules le jeudi 16 mars 2023, de 18h à 19h
March 15, 2023 13:05 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE SUR SA PLATEFORME DE DESTABILISATEURS DE MICROTUBULES LE JEUDI 16 MARS 2023, DE 18h A 19h Paris, 15 mars 2023, 18h AB Science SA...
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
March 15, 2023 13:05 ET
|
AB Science
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON ITS MICROTUBULE DESTABILIZER AGENTS (MDA) PLATFORM ON THURSDAY MARCH 16, 2023, FROM 6PM TO 7PM CET Paris, 15 March, 2023, 6pm CET AB Science SA...
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
March 13, 2023 13:10 ET
|
AB Science
PRESS RELEASE AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE IN A RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENT FROM THE VERY LOW DOSE ARM OF ITS AB8939 PHASE I/II CLINICAL TRIAL...